Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010079345) ANTIBODY-GUIDED FRAGMENT GROWTH
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2010/079345 International Application No.: PCT/GB2010/000040
Publication Date: 15.07.2010 International Filing Date: 12.01.2010
IPC:
G01N 33/68 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
Applicants:
UCB PHARMA S.A. [BE/BE]; 60, allée de la Recherche B-1070 Brussels, BE (AllExceptUS)
LAWSON, Alastair, David, Griffiths [GB/GB]; GB (UsOnly)
Inventors:
LAWSON, Alastair, David, Griffiths; GB
Agent:
THOMPSON, John; UCB Celltech 208 Bath Road Slough Berkshire SL1 3WE, GB
Priority Data:
0900425.012.01.2009GB
Title (EN) ANTIBODY-GUIDED FRAGMENT GROWTH
(FR) CROISSANCE DE FRAGMENTS GUIDÉE PAR DES ANTICORPS
Abstract:
(EN) The present invention relates to an improved method for drug discovery comprising using contact residue information derived from antibody-protein target interactions to help to direct the growth of small molecule fragments during the synthesis of a drug candidate. In particular, the present invention relates to the use of atomic structural information derived from antibody-protein interactions to guide the growth of small molecular fragments during lead optimisation, thus generating small molecule compounds which can alter the biological activity of a target protein.
(FR) La présente invention concerne un procédé amélioré de découverte de médicaments qui comprend l'utilisation d'informations de résidus de contact dérivées d'interactions cibles anticorps-protéine pour aider à diriger la croissance de fragments à petite molécule pendant la synthèse d'un médicament candidat. La présente invention concerne notamment l'utilisation d'informations structurales anatomiques dérivées d'interactions anticorps-protéine pour guider la croissance de petits fragments moléculaires pendant l'optimisation de la tête de série, ce qui permet de générer des composés à petite molécule qui peuvent modifier l'activité biologique d'une protéine cible.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
SG172816EP2386063JP2012515330US20110275857CN102272605CA2748928
EA201101059BRPI1006160IN5344/DELNP/2011